Trial Profile
A Study to Evaluate the Safety, Pharmacokinetics, and Haematopoietic Stem Cell Mobilisation of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Burixafor (Primary) ; Granulocyte colony-stimulating factors
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- Sponsors GPCR Therapeutics; TaiGen Biotechnology
- 23 May 2014 New trial record